Last 7 days
-10.7%
Last 30 days
-20.4%
Last 90 days
-66.2%
Trailing 12 Months
-70.9%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-07-03 | Ticho Barry | sold | -158,973 | 10.5982 | -15,000 | chief medical officer |
2023-06-21 | Allan Jonathan | sold | -26,252 | 13.4765 | -1,948 | general counsel & corp sec |
2023-06-01 | Ticho Barry | sold | -166,964 | 11.1309 | -15,000 | chief medical officer |
2023-05-04 | Ticho Barry | sold | -6,530 | 10.00 | -653 | chief medical officer |
2023-05-03 | Ticho Barry | sold | -250,366 | 10.1375 | -24,697 | chief medical officer |
2023-05-02 | Ticho Barry | sold | -55,133 | 10.0007 | -5,513 | chief medical officer |
2023-05-01 | Ticho Barry | sold | -249,767 | 10.0039 | -24,967 | chief medical officer |
2023-03-27 | Kaye Edward M. MD | acquired | 12,000 | 0.6 | 20,000 | ceo |
2023-02-06 | Ticho Barry | sold | -92,491 | 10.0153 | -9,235 | chief medical officer |
2023-02-03 | Ticho Barry | sold | -37,745 | 10.0306 | -3,763 | chief medical officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -1.89 | 33,381 | 165,828 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -68.45 | -1,578 | 1,062 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 20.29 | 98,791 | 283,417 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 13.5 | 209,355 | 676,355 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 163 | 78,444 | 111,689 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 18.74 | 149,348 | 439,232 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 13.79 | 309,424 | 993,916 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 48.84 | 14,000 | 29,000 | -% |
2023-08-14 | STATE OF WISCONSIN INVESTMENT BOARD | added | 27.39 | 355,375 | 923,439 | -% |
2023-08-14 | GILDER GAGNON HOWE & CO LLC | reduced | -1.66 | 110,282 | 542,917 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | rtw investments, lp | 9.8% | 3,870,981 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 4.06% | 1,602,045 | SC 13G/A | |
Feb 03, 2023 | redmile group, llc | 9.7% | 4,166,975 | SC 13G/A | |
Jan 25, 2023 | cowen financial products llc | 1.89% | 1,248,077 | SC 13G/A | |
Feb 14, 2022 | rtw investments, lp | 9.9% | 3,644,248 | SC 13G/A | |
Feb 14, 2022 | redmile group, llc | 6.1% | 2,246,668 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Jan 24, 2022 | cowen financial products llc | 5.09% | 1,871,529 | SC 13G | |
Jun 30, 2021 | skorpios trust | - | 6,905,121 | SC 13D |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 20, 2023 | 3 | Insider Trading | |
Sep 20, 2023 | 4 | Insider Trading | |
Sep 20, 2023 | 8-K | Current Report | |
Sep 18, 2023 | PRE 14A | PRE 14A | |
Sep 08, 2023 | 4 | Insider Trading | |
Aug 07, 2023 | 10-Q | Quarterly Report | |
Aug 07, 2023 | 8-K | Current Report | |
Jul 25, 2023 | 8-K | Current Report | |
Jul 06, 2023 | 4 | Insider Trading | |
Jun 23, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABBV | 271.1B | 56.0B | 2.30% | 9.45% | 31.22 | 4.84 | -2.31% | -31.27% |
BGNE | 258.4B | 1.8B | -1.67% | 25.43% | -149.17 | 142.72 | 69.45% | 14.65% |
VRTX | 91.3B | 9.5B | 0.45% | 22.78% | 27.14 | 9.61 | 13.83% | 5.33% |
REGN | 88.1B | 12.7B | -1.51% | 18.09% | 20.49 | 6.95 | -10.94% | -24.40% |
ALNY | 21.7B | 1.2B | -7.00% | -17.21% | -20.42 | 17.55 | 39.94% | -8.44% |
SRPT | 11.2B | 1.0B | 3.70% | 3.57% | -12.29 | 11.11 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.04 | 4.97 | 18.01% | 38.16% |
MID-CAP | ||||||||
BPMC | 3.0B | 225.6M | 0.04% | -28.00% | -5.4 | 13.27 | -2.11% | 21.02% |
MDGL | 2.9B | - | -10.01% | 147.80% | -8.93 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.63 | 6.49 | 20.50% | -42.46% |
MRTX | 2.1B | 27.2M | -14.18% | -57.07% | -2.89 | 78.22 | - | -14.43% |
SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.18 | 4.26 | 77.72% | 112.02% |
MGNX | 289.9M | 152.5M | -11.67% | 38.41% | 38.91 | 1.9 | 127.84% | 103.41% |
CRBP | 28.7M | - | 1.35% | 3552.08% | -0.62 | - | - | -31.51% |
-50.9%
94.6%
87.5%
80.4%
Y-axis is the maximum loss one would have experienced if Stoke Therapeutics was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | (In Millions) | ||||||
---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | -100.0% | - | 15.00 | 12.00 | 12.00 | 12.00 | 12.00 |
Operating Expenses | 1.9% | 121 | 119 | 117 | 111 | 103 | 97.00 |
S&GA Expenses | 0.3% | 40.00 | 40.00 | 39.00 | 38.00 | 37.00 | 34.00 |
R&D Expenses | 2.8% | 81.00 | 79.00 | 78.00 | 73.00 | 67.00 | 63.00 |
Net Income | -6.1% | -104 | -98.96 | -101 | -99.86 | -96.35 | -93.66 |
Net Income Margin | 100.0% | - | -6.80* | -8.15* | -8.20* | -7.73* | -7.81* |
Free Cashflow | 100.0% | - | -89.00 | -35.83 | -29.51 | -20.38 | -16.12 |
Balance Sheet | (In Millions) | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
Assets | -8.8% | 257 | 282 | 256 | 278 | 301 | 316 | 239 | 254 | 264 | 279 | 298 | 200 | 210 | 221 | 229 | 239 | 246 | 108 |
Current Assets | -8.9% | 246 | 270 | 244 | 265 | 289 | 306 | 229 | 245 | 260 | 275 | 294 | 195 | 206 | 216 | 226 | 237 | 244 | 106 |
Cash Equivalents | 0.9% | 192 | 190 | 114 | 113 | 68.00 | 84.00 | 145 | 149 | 169 | 268 | 287 | 191 | 202 | 211 | 222 | 233 | 243 | 105 |
Net PPE | -4.7% | 6.00 | 7.00 | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 |
Liabilities | -1.8% | 67.00 | 68.00 | 71.00 | 73.00 | 77.00 | 76.00 | 21.00 | 16.00 | 9.00 | 6.00 | 12.00 | 7.00 | 7.00 | 6.00 | 4.00 | 5.00 | 5.00 | 2.00 |
Current Liabilities | -30.7% | 22.00 | 32.00 | 31.00 | 29.00 | 28.00 | 23.00 | 17.00 | 12.00 | 8.00 | 6.00 | 11.00 | 7.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 2.00 |
Shareholder's Equity | -11.0% | 190 | 214 | 185 | 204 | 224 | 240 | 218 | 238 | 255 | 272 | 286 | 193 | 203 | 214 | 224 | 234 | 242 | 105 |
Retained Earnings | -9.6% | -350 | -319 | -297 | -271 | -245 | -220 | -196 | -171 | -149 | -127 | -110 | -95.72 | -82.03 | -69.07 | -58.03 | -47.87 | -39.27 | -25.71 |
Additional Paid-In Capital | 1.3% | 541 | 534 | 483 | 477 | 471 | 461 | 414 | 409 | 404 | 400 | 396 | 288 | 285 | 283 | 282 | 282 | 281 | 131 |
Shares Outstanding | 0.1% | 44.00 | 44.00 | 39.00 | 39.00 | 39.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 33.00 | 33.00 | 33.00 | 33.00 | 13.00 | 3.00 | 1.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -2.2% | -87,585 | -85,713 | -31,866 | -25,751 | -18,377 | -14,280 | -66,907 | -61,580 | -57,771 | -51,586 | -42,221 | -41,491 | -38,666 | -35,294 | -31,055 | -24,369 | -19,362 | -17,450 | -10,964 | -12,164 | -8,816 |
Share Based Compensation | 2.5% | 24,363 | 23,766 | 22,854 | 21,750 | 20,438 | 18,727 | 16,450 | 13,344 | 10,515 | 7,712 | 5,768 | 4,900 | 3,846 | 2,495 | 1,922 | 1,329 | 638 | 453 | 240 | 160 | 162 |
Cashflow From Investing | 16.3% | 166,312 | 142,985 | -45,882 | -56,575 | -129,103 | -212,004 | -76,426 | -88,313 | -83,318 | -644 | -1,050 | -1,529 | -1,843 | -2,154 | -1,634 | -1,148 | -1,081 | -918 | -925 | -2,064 | -652 |
Cashflow From Financing | -6.9% | 45,579 | 48,956 | 46,409 | 46,537 | 46,511 | 43,245 | 1,284 | 107,981 | 108,246 | 108,456 | 108,108 | 1,432 | -241 | 150,028 | 149,762 | 239,349 | 253,727 | 137,452 | 115,639 | 53,512 | 24,964 |
Consolidated statements of operations and comprehensive loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Income Statement [Abstract] | ||||
Revenue | $ (2,481) | $ 3,231 | $ 2,671 | $ 6,232 |
Operating expenses: | ||||
Research and development | 20,551 | 18,358 | 40,182 | 36,668 |
General and administrative | 10,230 | 10,111 | 20,442 | 19,596 |
Total operating expenses | 30,781 | 28,469 | 60,624 | 56,264 |
Loss from operations | (33,262) | (25,238) | (57,953) | (50,032) |
Other income: | ||||
Interest income (expense), net | 2,567 | 544 | 4,670 | 648 |
Other income (expense), net | 41 | 42 | 84 | 83 |
Total other income | 2,608 | 586 | 4,754 | 731 |
Net loss | $ (30,654) | $ (24,652) | $ (53,199) | $ (49,301) |
Net loss per share, basic | $ (0.69) | $ (0.63) | $ (1.23) | $ (1.29) |
Net loss per share, diluted | $ (0.69) | $ (0.63) | $ (1.23) | $ (1.29) |
Weighted-average common shares outstanding, basic | 44,188,464 | 39,258,358 | 43,367,032 | 38,358,936 |
Weighted-average common shares outstanding, diluted | 44,188,464 | 39,258,358 | 43,367,032 | 38,358,936 |
Comprehensive loss: | ||||
Net loss | $ (30,654) | $ (24,652) | $ (53,199) | $ (49,301) |
Other comprehensive gain (loss): | ||||
Unrealized gain (loss) on marketable securities | 219 | (592) | 796 | (1,108) |
Total other comprehensive loss | 219 | (592) | 796 | (1,108) |
Comprehensive loss | $ (30,435) | $ (25,244) | $ (52,403) | $ (50,409) |
Consolidated balance sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 192,060 | $ 113,556 |
Marketable securities | 39,387 | 116,039 |
Prepaid expenses | 10,950 | 10,932 |
Other current assets | 3,699 | 2,955 |
Interest receivable | 136 | 588 |
Total current assets | 246,232 | 244,070 |
Restricted cash | 569 | 569 |
Operating lease right-of-use assets | 3,646 | 4,753 |
Property and equipment, net | 6,472 | 6,675 |
Total assets | 256,919 | 256,067 |
Current liabilities: | ||
Accounts payable | 1,556 | 766 |
Accrued and other current liabilities | 12,222 | 15,748 |
Deferred revenue - current portion | 8,059 | 14,880 |
Total current liabilities | 21,837 | 31,394 |
Deferred revenue - net of current portion | 43,258 | 36,856 |
Other long term liabilities | 1,629 | 2,968 |
Total long term liabilities | 44,887 | 39,824 |
Total liabilities | 66,724 | 71,218 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity | ||
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 44,202,997 and 39,439,575 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 4 | 4 |
Additional paid-in capital | 540,919 | 483,170 |
Accumulated other comprehensive loss | (379) | (1,175) |
Accumulated deficit | (350,349) | (297,150) |
Total stockholders’ equity | 190,195 | 184,849 |
Total liabilities and stockholders’ equity | $ 256,919 | $ 256,067 |